<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang â€” Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang</h2>
    <div class="badge">2025-09-08T20:05:00+00:00</div>
    <ul>
      <li>08, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc.</li>
<li>NEXICART-2 primary endpoint was met at interim results presented at ASCO 2025.</li>
<li>NXC-201 is being evaluated in the U.S.</li>
<li>Phase 1/2 clinical trial; (iii) the risk that the Company may not be able to advance to registration-enabling studies for CAR-T NXC-201 or other product candidates, (iv) that success in early phases of pre-clinical and c</li>
<li>multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design.</li>
<li>Dr.</li>
<li>CEO Dr.</li>
    </ul>
    <p>
      <a class="btn" href="https://x.com/intent/tweet?text=Immix%20Biopharma%20Announces%20Strategic%20Investment%20by%20Houston%20based%20Goose%20Capital%2C%20led%20by%20founding%20member%20Dr.%20Nancy%20T.%20Chang%0A%E2%80%A2%2008%2C%202025%20%28GLOBE%20NEWSWIRE%29%20--%20Immix%20Biopharma%2C%20Inc.%0A%E2%80%A2%20NEXICART-2%20primary%20endpoint%20was%20met%20at%20interim%20results%20presented%20at%20ASCO%202025.%0A%E2%80%A2%20NXC-201%20is%20being%20evaluated%20in%20the%20U.S.%0A%E2%80%A2%20Phase%201%2F2%20clinical%20trial%3B%20%28iii%29%20the%20risk%20that%20the%20Company%20may%20not%20be%20able%20to%20advance%20to%20registration-enabling%20studies%20for%20CAR-T%20NXC-201%20or%20other%20product%20candidates%2C%20%28iv%29%20that%20success%20in%20early%20phases%20of%20pre-clinical%20and%20c%0A%E2%80%A2%20multi-center%20study%20for%20relapsed%2Frefractory%20AL%20Amyloidosis%20NEXICART-2%20%28NCT06097832%29%2C%20with%20a%20registrational%20design.%0A%E2%80%A2%20Dr.%0A%E2%80%A2%20CEO%20Dr.&url=https%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Fimmix-biopharma-announces-strategic-investment-by-houston-based-goose-capital-le%2F" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a class="btn" href="https://finance.yahoo.com/news/immix-biopharma-announces-strategic-investment-200500034.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>